Skip to main content
. 2018 Mar 2;5(3):ofy004. doi: 10.1093/ofid/ofy004

Table 1.

Summary of Patient Demographics and Clinical Characteristics by Third Component of First ART Regimen

EFV-Based Boosted PI Combined
Characteristics (n = 12 898) (n = 1621) (n = 14 519) P
Age at ART initiation, y 37 (30–45) 35 (29–44) 37 (30–45) <.001
Male, n (%) 9864 (76) 956 (59) 10 820 (75) <.001
CD4 at ART initiation, cells/µL 175 (66–289) 217 (79–351) 178 (67–295) <.001
Missing CD4 at ART, n (%) 1208 (9) 203 (13) 1411 (10)
Late ART initiation, n (%) 7863 (61) 804 (49) 8667 (60) <.001
Probable route of HIV transmission, n (%) <.001
Heterosexual 3874 (30) 665 (41) 4539 (31)
MSM 4100 (32) 529 (33) 4629 (32)
Other 130 (1) 25 (2) 155 (1)
Unknown 4794 (37) 402 (25) 5196 (36)
NRTI backbone, n (%) <.001
3TC/ABC 483 (4) 126 (8) 609 (4)
3TC/AZT 8234 (64) 858 (53) 9092 (63)
3TC/D4T 744 (6) 60 (4) 804 (6)
3TC/TDF 1754 (14) 351 (22) 2105 (14)
FTC/TDF 1683 (13) 226 (14) 1909 (13)
Patients per site, n (%) <.001
Argentina 1680 (13) 345 (21) 2025 (14)
Brazil 2258 (18) 507 (31) 2765 (19)
Chile 1109 (9) 186 (11) 1295 (9)
Haiti 3824 (30) 234 (14) 4058 (28)
Honduras 800 (6) 26 (2) 826 (6)
Mexico 873 (7) 145 (9) 1018 (7)
Peru 2354 (18) 178 (11) 2532 (17)
Year of ART initiation 2009 (2007–2012) 2011 (2008–2013) <.001

Continuous variables are reported as medians (interquartile range). CCASAnet participating centers per country are: Hospital Fernandez and Centro Medico Huesped in Buenos Aires, Argentina; Instituto de Pesquisa Clinica Evandro Chagas, Fundacão Oswaldo Cruz in Rio de Janeiro, Brazil; Fundación Arriarán in Santiago, Chile; Le Groupe Haitien d’Etude du Sarcome de Kaposi et des Infections Opportunistes in Port-au-Prince, Haiti; Instituto Hondureño de Seguridad Social and Hospital Escuela Universitario in Tegucigalpa, Honduras; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City, Mexico; and Instituto de Medicina Tropical Alexander von Humboldt in Lima, Peru.

Abbreviations: 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; D4T, stavudine; EFV, efavirenz; FTC, emtricitabine; late ART Initiation, CD4 <200 or AIDS-defining event at ART initiation; MSM, men having sex with men; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TDF, tenofovir.